Pfizer (PFIZER) Q2 FY27 Profit Doubles on One-Time Gain, But Core Growth Holds Steady
Pfizer's Q2 FY27 net profit surged 66% year-on-year, significantly boosted by a ₹132 crore one-off gain from a product discontinuation, while underlying operations grew at a steady pace.
Pfizer's Q2 FY27 profit jumped 66% to ₹313 crore, largely due to a one-time exceptional gain. Underlying profit before this gain grew 14%, supported by a 13% rise in revenue, though expenses also climbed.
Pfizer India’s September quarter delivered a headline profit surge, but the story is split between a one-time windfall and steady underlying business momentum. The company’s net profit more than doubled sequentially, yet a significant portion came from a non-recurring event, setting a high bar that operating performance alone cannot sustain.
Revenue rose 13.2% year-on-year to ₹727 crore, continuing a steady growth trajectory. Profit before tax and exceptional items, a clearer view of operations, grew 13.9% to ₹291 crore, according to a Kotak Neo report. The reported net profit margin of 43.1% is a sharp jump from 31.3% last quarter, but this is largely flattered by the one-off gain.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ2 FY27 | PreviousQ1 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 727.0YoY +13% | 653.2 | 642.3 |
| Profit (₹ Cr) | 313.0YoY +66% | 204.5 | 189.0 |
| Net Profit Margin (%) | 43.1YoY +47% | 31.3 | 29.4 |
The One-Off That Skewed the Print
The standout figure was a ₹132.06 crore exceptional gain, net of expenses, as reported by Kotak Neo. This resulted from the parent company discontinuing the manufacture of Minipress XL, for which Pfizer India received a lump-sum payment. This single item explains the bulk of the quarter's profit jump and the dramatic margin expansion, creating a base effect that will not repeat.
Underlying Operations and Rising Costs
Stripping out the exceptional gain, the business showed resilience. Profit before exceptional items grew at a pace slightly ahead of revenue. However, total expenses rose 12.6% year-on-year, driven by higher purchases of stock-in-trade and employee costs, as noted in a ScanX report. This suggests inflationary pressures are present, even as the company manages to deliver operating leverage.
The market reaction was positive, with the stock closing up over 5% on results day. Analyst sentiment, as tracked by S&P Global, remains bullish with a consensus 'Strong Buy' and an average price target of ₹6,659, according to a Stockwatch report. This reflects confidence in the company's core portfolio and new launches like the Prevenar 20 vaccine.
The Regulatory Shadow
A key headwind emerged just after the quarter. A Biospectrum Asia report states that recent drug price revisions by India's National Pharmaceutical Pricing Authority (NPPA) could cost the industry $160 million annually. Multinationals like Pfizer are expected to be among the most impacted, with an estimated annual loss of around $8 million (₹48 crore). This introduces a margin pressure that new product launches must offset.
Key Points
- Reported net profit of ₹313 crore was boosted by a non-recurring ₹132 crore exceptional gain from a product discontinuation.
- Underlying profit before this gain grew a healthy 13.9%, supported by 13.2% revenue growth.
- Rising input and employee costs pressured the expense line, which grew 12.6% year-on-year.
- The company faces a new headwind from recent drug price ceiling revisions that could impact future revenue.
Hexa Perspective
The quarter presents a tale of two profits: a spectacular reported number and a solid, single-digit underlying performance. Investors must look past the one-off gain to assess the health of the business, which continues to grow steadily amid sector-wide cost pressures.
The coming quarters will test Pfizer's ability to maintain momentum. Success will depend on new launches like Prevenar 20 gaining traction and offsetting the impending impact of price regulations. The stock's significant discount to analyst targets suggests the market is weighing these regulatory risks against the company's stable core growth.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.